Cancer Center/Regenerative Medicine Translational Laboratory
The Cancer Center/Regenerative Medicine Translational Laboratory performs translational development of novel cell engineering methods leading to clinical production of novel therapies across a wide range of applications.
Production Assistance for Cellular Therapy (PACT)
The mission of PACT is to offer translational services and cell product manufacturing for pre-clinical studies to investigators at no charge under a National Heart, Lung, and Blood Institute (NHLBI) grant.
UMMC Cell Therapy Laboratory, Fairview
The Clinical Cell Therapy Laboratory develops novel cell engineering methods, performs validation studies of such methods, and provides cGMP clinical-scale production for the University of Minnesota and external contractors.
Pancreatic Islet Cell Laboratory
The Pancreatic Islet Transplant Program, one of the more active of such programs in the nation, performs over 50 autologous and allogeneic isolation annually.
The Targeted Immunotherapy program is interested in bioengineering drugs that are antibody-based and therefore selectively target chemotherapy resistant cancer. They are genetically engineering new drugs and testing these in experimental animal models. These new immunotherapy drugs kill by a mechanism entirely different than chemotherapy. The program believes it is in a unique position to address some of the most pressing issues including the engagement of the innate immune system to kill cancer. A new genre of drugs show that cancer metastasis can effectively be combated by engaging the immune system to selectively kill tumors. They developed a new drug platform that works extremely well in recruiting NK cells to kill leukemia cells and carcinoma. Products have included the development of biological drugs against chemotherapy refractory cancer, such as DT2219ARL: AntiCD22, and AntiCD19 + Diphtheria. Read about Targeted Immunotoxin laboratory goals.